Trial Profile
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms NAXOS; SNIIRAM
- Sponsors Bristol-Myers Squibb
- 16 May 2022 Status changed from active, no longer recruiting to completed.
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 16 Jun 2020 Results published in the Stroke